Crescent Biopharma, Inc. (CBIO) vs NeoGenomics, Inc. (NEO)
A side-by-side comparison of Crescent Biopharma, Inc. and NeoGenomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CBIO
Crescent Biopharma, Inc.
$13.58HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
NEO
NeoGenomics, Inc.
$16.66HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
Total return — CBIO vs NEO
growth of $100 · dividends reinvested · last 10yCBIO -92.7% (-23.0%/yr)NEO +134.5% (+8.9%/yr)NEO compounded faster over this window
Log scale — wide-divergence pair
CBIO NEO
CBIO vs NEO: by the numbers
- •CBIO is the larger company ($504M vs $428M market cap).
- •Both run net losses; NEO's is the smaller (-6.77% vs -1371.51% net margin).
- •CBIO grew revenue faster over the past five years (39.89% vs 9.41% CAGR).
Metrics side by side
Valuation
| Metric | CBIO | NEO |
|---|---|---|
| Forward P/E | N/A | 91.17 |
| P/S ratio | 42.43 | 0.56 |
| P/B ratio | 3.17 | 0.54 |
Profitability
| Metric | CBIO | NEO |
|---|---|---|
| Gross margin | 100.00% | 42.92% |
| Operating margin | -1407.52% | -8.63% |
| Net margin | -1371.51% | -6.77% |
| ROE | -99.83% | -6.60% |
| ROIC | -102.59% | -5.29% |
Growth (annualized)
| Metric | CBIO | NEO |
|---|---|---|
| Revenue CAGR (5Y) | 39.89% | 9.41% |
| Total return CAGR (5Y) | -24.40% | -15.14% |
Frequently asked
- Which has grown faster, CBIO or NEO?
- Over the past five years, CBIO grew revenue faster — CBIO at a 39.89% CAGR versus NEO at 9.41%.
- How have CBIO and NEO total returns compared?
- Over the past 10 years, CBIO delivered -22.94% and NEO delivered 8.90% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Crescent Biopharma ROENeoGenomics ROECrescent Biopharma operating marginNeoGenomics operating marginCrescent Biopharma revenue growthNeoGenomics revenue growthCrescent Biopharma free cash flowNeoGenomics free cash flow
Crescent Biopharma & NeoGenomics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.